secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-05-18T13:33:34+00:00
Accession:  0001193125-26-228133
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts
--------------------------------------------------------------------------------

- Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
- Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.
- PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.
- Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.
- Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-228133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer